LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio’s Vision for Europe: Innovation, Investment, Excellence

29/06/2022
PRESS RELEASE
June 30, 2022, Brussels - EuropaBio, Europe’s leading life sciences industry association, presents its vision for European biotechnology and kicks off a campaign Vision for Europe: Innovation, Investment, Excellence. The campaign demonstrates how European healthcare biotechnology delivers benefits across society, from high-skilled jobs and economic strength to ground-breaking treatments that change and save lives, and the framework needed for success on a global scale.

Europe is entering a period of significant and impactful legislative changes that will shape the future of healthcare in Europe by enabling the digital and sustainable transitions. The revision of pharmaceutical legislation and the Orphan and Paediatric Regulations, the creation of a European Health Data Space and the latest progress on Advanced Therapy Medicinal Products (ATMPs) will determine Europe’s innovation landscape. This will define Europe’s capacity to translate science into novel therapies, the ability of small companies to start and grow, and long-term investment decisions that will boost Europe’s competitiveness.

Claire Skentelbery, EuropaBio Director General, commented: “Europe is a leader in Research, Development and Innovation and this has to translate rapidly into innovative and life saving treatments that could be easily accessible to patients. We have a vision for Europe that creates an environment for start-ups, SMEs and large companies that enables their growth and helps to attract, maintain, and grow investments in innovative healthcare biotech discoveries. We are joining forces with innovators, policy-makers and other key actors to make the EU the world’s most advanced region in healthcare biotechnology.’’

Neil Mulcock, Chair of EuropaBio Healthcare Biotechnology council representing Gilead added: ‘The EU has the potential to become the world’s most innovative biotech region. With that in mind EuropaBio welcomes the EC’s intention of supporting “a competitive and innovative European pharmaceutical environment” (as stated in the EC’s 2020 Pharmaceutical Strategy for Europe). To realise this goal the EU must address the factors that are causing Europe to fall behind, such as creating a world class regulatory framework and an environment that incentivises and rewards innovation. A successful pharmaceutical sector in the EU not only has the prospect of improving public health and saving lives but can also create jobs and wealth for our economy.’

EuropaBio’s Board representatives shared their own visions on European healthcare biotechnology:

• lead the world in scientific and industrial INNOVATION. “The EU needs to make sure that our single market works for innovation. New medicines do not fall from trees – they require the right eco-system and careful nurturing. Europe is the richest continent in the world with the highest skills level and the best innovators” David Earnshaw, EuropaBio board member, commented.

• boost and attract INVESTMENTS in biotech. “The EU has the potential to become the world’s most innovative biotech region by creating the right environment to attract investments and excellence’’, Luana Banu, EuropaBio board member, said.

• become a global centre of EXCELLENCE for biotech. “Research and development is not an engine you can simply turn off and on. It is an interdependent ecosystem requiring nurture and care in order to create the right environment for innovation to flourish” Andrew Topen, former Chair of EuropaBio Board, stated.

To learn more about EuropaBio vision for Europe, browse the freshly launched knowledge hub – featuring EuropaBio and member reports, white papers, case studies, publications, consultation responses and infographics that provide insight on a range of topics related to healthcare innovation, investment and excellence in Europe: https://www.europabio.org/vision-for-europe/

EuropaBio’s Vision for Europe: Innovation, Investment, Excellence


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.